Berthony Deslouches




Berthony Deslouches



Country of Residence

USA; birthplace, Haiti

Short Bio

Assistant Professor in Environmental and Occupatonal Health, Public Health, University of Pittsburgh
Areas of expertise: biochemistry, microbiology, antimicrobial therapeutics

Professional Affiliation

University of Pittsburgh Graduate School of Public Health, Department of Environmental and Occupational Health

Humanitarian Organization

ALPAM Group, Inc, Not-for-profit organization with the mission to improve Haitian lives



Professional appointments
  • 2019-Present, Assistant Professor, Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh
  • 2015-2019, Research Assistant Professor, Department of Microbiology and Molecular Genetics, University of Pittsburgh
Education and training
  • 2008-2015, Postdoctoral training; University of Pittsburgh and Jefferson University
  • 2008, MD, Medicine; Medical Scientist Training Program (MD/PhD), University of Pittsburgh
  • 2006, PhD, Microbiology and Molecular Genetics; Medical Scientist Training Program (MD/PhD), University of Pittsburgh
  • 1996, MA, Biochemistry; City College of the City University of New York
  • 1993, BS, Anthropology and Biochemistry; City College of the City University of New York
Awards and Honors

a)  Patent

Co-inventor with Dr. Peter Di, patent filed in 2017; title: Novel peptide Antibiotics in Effectively Treating Drug-Resistant Microbial Infection; University of Pittsburgh.

b) Committees Served Within the University of Pittsburgh
Representative member of the Faculty Diversity Committee for the Department of Environmental and occupational health, Graduate School of Public Health (2018-present)



1)       NIH/NIGMS 1R01GM125917

Title:  Determinants and Mechanisms of Efficacy of Peptide Antibiotics as Novel Sepsis Therapy

PI:  Berthony Deslouches, MD, PhD

Annual direct cost:  250,000

Period of support:  July 2018-2023

2)        NIH/NIGMS 1R01GM125917-S1 Instrument grant, administrative supplement

Direct cost:  $249,900

Period of support:  August 2019-2020

Teaching and mentorship

a)    Courses Taught

Pathophysiology of Disease (graduate course), Department of Environmental and Occupational

Health, Graduate School of Public health (spring 2018-present);

b)    Graduate mentorship

New T32 mentor, Pitt Training Program on antimicrobial resistance (2019) as part of my affiliation with the Center for Innovative Antimicrobial Therapy, Infectious Diseases Division, Department of Medicine

Invited talks

Recent Oral Presentations by Invitation
Invited speaker, the 3rd annual Cystic Fibrosis Research Center Retreat, Pittsburgh, PA, 2017.
Invited speaker, Duquesne University, Department of Biological Sciences, Pittsburgh, PA, 2019

Humanitarian contributions


Co-Director, ALPAM Group, Inc., Haitian organization with headquarters in Florida, USA
Ad hoc Reviewing for Journals
·         PLOS ONE

·         Antimicrobial Agents and Chemotherapy

·         Oncotarget

·         Journal of medical Microbiology

·         Science Translational Medicine


Recent Publications (2016-2019)

1.       Abdelbaqi S, Deslouches B, Steckbeck J, Montelaro R, Reed DS. Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis, and Burkholderia pseudomallei. J Med Microbiol 2016 Feb;65(2):188-94. PubMed PMID: 26673248

2.       Melvin JA, Lashua LP, Kiedrowski MR, Yang G, Deslouches B, Montelaro RC, Bomberger JM.  Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus- Bacterium Coinfection. mSphere. 2016 May 4;1(3). PubMed PMID: 27303744

3.       Deslouches B, Hasek ML, Craigo JK, Steckbeck JD, Montelaro RC. Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine. J Med Microbiol. 2016 Jun;65(6):554-65. PubMed PMID: 27046192

4.       Lashua LP, Melvin JA, Deslouches B, Pilewski JM, Montelaro RC, Bomberger JM. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells. J Antimicrob Chemother. 2016 Aug;71(8):2200-7. PubMed PMID: 27231279

5.       Hasek M. L., Steckbeck D. J., Deslouches B, Craigo J, and Montelaro RC. Engineered Cationic Antimicrobial Peptides Containing Cholesterol Interacting Motifs to Target Viral Envelopes. J Antivir Antiretrovir. 2017 Apr 30;9:021-032

6.       Deslouches B, Di YP. Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget, 2017 Jul 11;8(28):46635-51: PubMed PMID:28422728

7.       Chen C, Deslouches B, Montelaro RC, Di YP. Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of P. aeruginosa pneumonia. Clin Microbiol Infect. 2017 Sep 4.   [Epub ahead of print] PubMed PMID: 28882728

8.       Mandell JB, Deslouches B, Montelaro RC, Shanks RMQ, Doi Y, Urish KL. Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. Sci Rep. 2017 Dec 22;7(1):18098. PubMed PMID: 29273750.

9.       Deslouches B, Di YP. Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections. Clin Surg. 2017 Nov;2. pii: 1740. Epub 2017 Nov 16. PMID: 30135956

10.     Lin Q, Deslouches B, Montelaro RC, Di YP. Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. Int J Antimicrob Agents. 2018 May 9. pii: S0924-8579(18)30128-6. doi: 10.1016/j.ijantimicag.2018.04.019. [Epub ahead of print], PMID: 29753132

11.     Yu Z, Deslouches B, Walton WG, Redinbo MR, Di YP. Enhanced biofilm prevention activity of a SPLUNC1-derived antimicrobial peptide against Staphylococcus aureus. PLoS One. 2018 Sep 14;13(9):e0203621. doi: 10.1371/journal.pone.0203621. eCollection 2018. PMID: 30216370

12.     Kumagai A, Dupuy FG, Arsov Z, Elhady Y, Moody D, Ernst RK, Deslouches B, Montelaro RC, Peter Di Y, Tristram-Nagle S. Elastic behavior of model membranes with antimicrobial peptides depends on lipid specificity and d-enantiomers. Soft Matter. 2019 Feb 20;15(8):1860-1868. doi: 10.1039/c8sm02180e. PMID: 30702120

13.     Jiang S, Deslouches B, Chen C, Matthew E, Di YP. Antibacterial Properties and Efficacy of a Novel SPLUNC1-Derived Antimicrobial Peptide, α4-Short, in a Murine Model of Respiratory Infection. DOI: 10.1128/mBio.00226-19,; in press.

Berthony Deslouches’s Friends